GW Pharmaceuticals plc

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

34 documents for GW Pharmaceuticals plc

- GW Pharmaceuticals plc - New Shares Issued Raising $11.2m (6.6m).
PORTON DOWN, UK -- GW Pharmaceuticals plc (GWP: AIM), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex[R], to...
- Business Wire
- August 06, 2009
- Premerger notification waiting periods; early terminations,
...Otsuka Pharmaceutical GW Pharmaceuticals plc. GW Pharma Ltd. Co., Ltd. 20070919...............
- FR, April 04, 2007
- Notices
- Federal Trade Commission
- Research and Markets: GW Pharmaceuticals PLC Analysed in New Product Pipeline Report.
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c77275) has announced the addition of GW Pharmaceuticals PLC - Prod...
- Business Wire
- December 14, 2007

- Medicinal and Botanical Products
... comfortable with plant-derived pharmaceuticals. The majority of the medicinal plants harvested fo...
- Encyclopedia of Global Industries, 4th ed.
- Chemicals
- Research and Markets: Neuropathic Pain Report - Drug Pipeline Analysis and Market Forecasts to 2015.
..., Cephalon Inc., UCB S.A., Newron Pharmaceuticals, EpiCept Corporation, GW Pharmaceuticals, Johnson ...
- Business Wire
- January 06, 2010
- Glaxosmithkline and the Irs Finally Find Relief with Zantac
When it comes to transfer pricing, even the most seasoned tax professionals can find themselves with a stomachache. Transfer pricing is at the heart of a long-running dispute between the IRS and a corporate taxpayer, which resulted in the largest settlement in IRS history. The primary issue in the GlaxoSmithKline (GSK) case was the transfer price at which the UK parent GlaxoSmithKline PLC, sold drugs to its US subsidiary. Very little information is available from the various advance pricing agreements executed by the IRS. The SmithKline Beecham advanced pricing agreement, which was obtained by Tax Analysts, was a major factor in the recently settled litigation between GSK and the IRS. Developing a drug and getting it to market involves numerous different costs, such as research and deve...

... Beecham by SmithKline Beecham Pharmaceuticals Co. (LabCo.), a manufacturing concern in Puerto Ri...
- CPA Journal, The
- Vol. 78 Nbr. 6, June 2008
- Healthshares(Tm) Announces Quarterly Rebalancing of Healthshares(Tm) Indexes
To: MEDICAL EDITORS Contact: Melissa Kanter of Edelman for XShares, +1-212-704-8261, melissa.kanter@edelman.com

...Add Indevus Pharmaceuticals, Inc. Nasdaq: IDEV. Neuroscience. Drop Schwarz Pha...
- U.S. Newswire
- September 17, 2007
- New Partner and US Combination Boosts Employee Share Incentives Group at Mayer, Brown, Rowe & Maw LLP.
... Antibody Technology Group plc, GW Pharmaceuticals plc and St Modwen Properties plc. . For further in...
- Mondaq Business Briefing
- Nbr. 2003, May 2003
- Research and Markets: Bayer is Aiming to Grow the Pharmaceuticals Business in Line with the Market between 2007 and 2009, at 5-6 Per Cent Per Annum.
DUBLIN, Ireland -- Research and Markets(http://www.researchandmarkets.com/research/aa87c5/bayer_performance) has announced the addition of the "Bayer:...
- Business Wire
- January 30, 2009
- Research and Markets: With Successful Life-Cycle Management, Bayer's Established Products Levitra, Kogenate, Trasylol and Avalox Continue to Drive Sales.
...'s future strategic focus within pharmaceuticals. . Current Growth Drivers . With successful life-c...
- Business Wire
- May 23, 2006